Skip to main content

Table 3 Progression-free, median overall, and 5-year median survival for primary and recurrent advanced ovarian cancer following peritonectomy with or without HIPEC

From: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in an Australian institution: lessons from 20 years’ experience

Survival

Primary OC

n = 11

Recurrent OC

n = 30

Platinum Sens*

n = 13

Platinum Res**

n = 17

Progression-free (months)

30.0

6.7

30.8

6.5

Median overall (months)

67.0

18.1

31.5

12.8

5-year (%)

27.0

3.0

  
  1. *Platinum Sens = platinum sensitive recurrent disease
  2. **Platinum Res = platinum resistant recurrent disease